• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Technology Bio Tech

PolyNovo Share Price in Reverse upon New Funding (ASX:PNV)

Like 0

By Lachlann Tierney, Tuesday, 14 July 2020

Shares in Melbourne-based medtech company Polynovo Ltd [ASX:PNV] have slid for a fifth consecutive day. Today’s dip in the PNV share price comes on the back of new funding for clinical trials of its proprietary NovoSorb regeneration solution...

Shares in Melbourne-based medtech company Polynovo Ltd [ASX:PNV] have slid for a fifth consecutive day.

Today’s dip in the PNV share price comes on the back of new funding for clinical trials of its proprietary NovoSorb regeneration solution.

Shares in the medtech giant are trading lower at the time of writing, dropping 0.86% or two cents, to trade at $2.32 per share.

The ASX health care sector is down 104.5 points or 0.3%, while the broader ASX 200 is also down 0.32%.

ASX PNV Share Price Chart - Polynovo

Source: Tradingview.com

New funding not bad news

The PNV share price appears as if it is being pulled down with others on ASX’s health care sector.

However, today’s announcement is a relatively positive one.

PNV has secured US$15 million from Biomedical Advanced Research and Development Authority (BARDA) to support the clinical trial program of NovoSorb BTM.

BARDA is part of the US Department of Health and Human Services.

The trial is intended to gather data on the effectiveness of NovoSorb BTM in the treatment of full thickness burns.

PolyNovo said it would make a modest co-funding and ‘in kind’ contribution to the trial with the final budget to be announced after US FDA approval.

Should the trials be a success, we could see a similar reaction in share price like we did in April.

Record US sales

Last Friday PNV announced June 2020 was a new record sales month in the US.

Since April, the company has opened seven new hospital accounts in the country.

Throughout FY2020 there has been a 67% increase in hospital accounts in the US.

PNV said they have had success opening new accounts and achieving record sales, despite the impacts of COVID-19.

Four Innovative Aussie Stocks that Could Shoot Up after Lockdown.

Sales have also been ticking upwards in Europe and have just commenced in the UK.

PNV echoed its previous guidance that product sales for FY20 are likely to at least double FY19.

With sales in the June quarter up 33% from the March quarter in FY20.

So, why the fall in share price?

PNV has had an incredible run up in over the past five years, passing the $3 mark just before the crash in March.

Since starting out as a speculative microcap stock, PNV now has a market cap of $1.55 billion.

The thing with larger-capped stocks is they tend to move with the market, more than their smaller-capped peers.

Which could explain the slump in share price despite the encouraging news.

However, continued successful trials in the US could help the share price edge higher.

If you feel like you’ve missed the boat with PolyNovo, check out our free report on four well positioned small-cap stocks. It features two stocks in e-commerce and two stocks whose focus is safety.

Regards,

Lachlann Tierney,
For Money Morning

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Lachlann Tierney

Lachlann’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • The rock hunters are back in the game
    By Callum Newman

    Expect more capital raisings and drilling campaigns from the junior gold sector. It’s another example of things heating up.

  • The ‘Rich Dad, Poor Dad’ of Mining
    By James Cooper

    Former geologist, James Cooper, outlines his ‘Rich Dad, Poor Dad’ experience as a geologist by contrasting two companies he worked for.

  • America’s next Vietnam begins
    By Callum Newman

    I remember George W Bush on a US carrier declaring ‘Mission Accomplished’ when it came to Iraq in the second Gulf war. That was in 2003. The war was still going in 2011. Iraq became a failed state, instead of a flourishing democracy. The Iranians aren’t stupid.

Primary Sidebar

Latest Articles

  • The rock hunters are back in the game
  • The ‘Rich Dad, Poor Dad’ of Mining
  • America’s next Vietnam begins
  • Are we at war with China?
  • Looking for the Catalyst: European Rearmament

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988